This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2002 Sep 1;31(1):115-7.

doi: 10.1097/00126334-200209010-00015.

Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy

Stéphanie Basso, Caroline Solas, Anne-Marie Quinson, Isabelle Ravaux, Isabelle Poizot-Martin, J Bacconier, Alain Durand, Bruno Lacarelle

PMID: 12352158
DOI: 10.1097/00126334-200209010-00015

Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy

Stéphanie Basso et al. J Acquir Immune Defic Syndr. 2002.

. 2002 Sep 1;31(1):115-7.

doi: 10.1097/00126334-200209010-00015.

Authors

Stéphanie Basso, Caroline Solas, Anne-Marie Quinson, Isabelle Ravaux, Isabelle Poizot-Martin, J Bacconier, Alain Durand, Bruno Lacarelle

PMID: 12352158
DOI: 10.1097/00126334-200209010-00015

No abstract available

PubMed Disclaimer

Similar articles

Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C, Tribut O. Arvieux C, et al. Drugs. 2005;65(5):633-59. doi: 10.2165/00003495-200565050-00005. Drugs. 2005. PMID: 15748098 Review.
Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.
De Luca A, Baldini F, Cingolani A, Di Giambenedetto S, Hoetelmans RM, Cauda R. De Luca A, et al. J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):359-66. doi: 10.1097/00126334-200404010-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15097152 Clinical Trial.
Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chêne G, Clavel F, Girard PM. Taburet AM, et al. Clin Pharmacol Ther. 2004 Apr;75(4):310-23. doi: 10.1016/j.clpt.2003.12.013. Clin Pharmacol Ther. 2004. PMID: 15060509 Clinical Trial.
Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
Fätkenheuer G, Römer K, Kamps R, Salzberger B, Burger D. Fätkenheuer G, et al. AIDS. 2001 Nov 23;15(17):2334-5. doi: 10.1097/00002030-200111230-00021. AIDS. 2001. PMID: 11698713 No abstract available.
Pharmacokinetics of Telzir (fosamprenavir).
Wilkins E. Wilkins E. J HIV Ther. 2004 Nov;9(4):87-91. J HIV Ther. 2004. PMID: 15731740 Review.

See all similar articles

Cited by

Double-boosted protease inhibitor antiretroviral regimens: what role?
Ribera E, Curran A. Ribera E, et al. Drugs. 2008;68(16):2257-67. doi: 10.2165/0003495-200868160-00001. Drugs. 2008. PMID: 18973392 Review.
Drug interactions with antiretrovirals.
Catanzaro LM, Slish JC, DiCenzo R, Morse GD. Catanzaro LM, et al. Curr HIV/AIDS Rep. 2004 Jun;1(2):89-96. doi: 10.1007/s11904-004-0013-z. Curr HIV/AIDS Rep. 2004. PMID: 16091228 Review.
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C, Tribut O. Arvieux C, et al. Drugs. 2005;65(5):633-59. doi: 10.2165/00003495-200565050-00005. Drugs. 2005. PMID: 15748098 Review.
Management of HIV-infected patients with multidrug-resistant virus.
Harris M, Montaner JS. Harris M, et al. Curr HIV/AIDS Rep. 2004 Sep;1(3):116-21. doi: 10.1007/s11904-004-0017-8. Curr HIV/AIDS Rep. 2004. PMID: 16091231 Review.
Pharmacokinetic enhancement of protease inhibitor therapy.
King JR, Wynn H, Brundage R, Acosta EP. King JR, et al. Clin Pharmacokinet. 2004;43(5):291-310. doi: 10.2165/00003088-200443050-00003. Clin Pharmacokinet. 2004. PMID: 15080763 Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer
Medical
- MedlinePlus Health Information